Bethel, M. Angelyn
Sourij, Harald
Stevens, Susanna R.
Hannan, Karen
Lokhnygina, Yuliya
Adler, Amanda I.
Peterson, Eric D.
Holman, Rury R.
Lopes, Renato D.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine
https://doi.org/10.2337/dc20-2806
Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS
https://doi.org/10.1186/s12933-019-0921-2
Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype
https://doi.org/10.2337/dc17-1778
Hispanic representation in diabetes cardiovascular outcomes trials
https://doi.org/10.1136/bmjdrc-2019-000656
Contemporary and Novel Therapeutic Options for Hypertriglyceridemia
https://doi.org/10.1016/j.clinthera.2015.08.001
DPP-4 Inhibitors and Respiratory Infection: A Systematic Review and Meta-analysis of the Cardiovascular Outcomes Trials
https://doi.org/10.2337/dc20-2018
Pancreatic Safety of Sitagliptin in the TECOS Study
https://doi.org/10.2337/dc15-2780
Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial (Results)
https://doi.org/10.2337/dc17-1091
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
https://doi.org/10.1016/s0140-6736(13)62154-6
Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes
https://doi.org/10.2337/cd16-0063
2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
https://doi.org/10.1016/s0140-6736(12)60691-6
Time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease
https://doi.org/10.1186/s12933-023-01802-x
Do Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Cause Heart Failure?
https://doi.org/10.1016/j.clinthera.2014.10.009
Article History
Received: 27 September 2022
Accepted: 15 March 2023
First Online: 28 March 2023
Declarations
:
: The trial was designed and overseen by a steering committee, and an independent data and safety monitoring committee performed regular safety surveillance. All patients provided written informed consent. Institutional review board approval was required at all participating institutions.
: Not applicable.
: MAB is an employee of and stockholder in Eli Lilly & Co. HS has received grant support from Boehringer Ingelheim, Eli Lilly, MSD, NovoNordisk and Sanofi as well as personal fees from AstraZeneca, Amgen, Boehringer Ingelheim, Bayer, Eli Lilly, MSD, Novartis, NovoNordisk, Sanofi Aventis. YL has received grants from Merck, Janssen Research & Development, AstraZeneca, GlaxoSmithKline, and Bayer HealthCare AG. EDP has received research support from Janssen, Merck, Bristol Myers Squibb, Amgen, and Esperion, and has had consulting associations with Bristol Myers Squibb, Pfizer, Amgen, Janssen, Boehringer-Ingelheim, and Livongo. RRH reports research support from AstraZeneca, Bayer and Merck Sharp & Dohme, and personal fees from Anji Pharmacueticals, Bayer, Novartis and Novo Nordisk. RDL has received research grants from Bristol Myers Squibb, GlaxoSmithKline, Medtronic, and Pfizer; consulting fees from Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Medtronic, Merck, Pfizer, and Portola Pharmaceutical. The other authors have no disclosures.